2.87
+9.96%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Eledon Pharmaceuticals
From its filings with the US Securities and Exchange Commission
Eledon Pharmaceuticals is based in Irvine, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ELDN. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2016, it reported revenue of $0.
Eledon is a clinical stage biotechnology company using our immunology expertise in targeting the CD40 Ligand (“CD40L”) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (“ALS”). Our lead compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that we believe has broad therapeutic potential. We believe the central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention.
Tegoprubart is engineered to potentially both improve safety and provide pharmacokinetic, pharmacodynamic, and dosing advantages compared to other anti-CD40 approaches. The CD40L/CD40 pathway is recognized for its prominent role in immune regulation. CD40L is primarily expressed on activated CD4+ T cells, platelets and endothelial cells while the CD40 receptor is constitutively expressed on antigen presenting cells such as macrophages and dendritic cells, as well as B cells. By blocking CD40L and not the CD40 receptor, tegoprubart inhibits both the CD40 and CD11 costimulatory signaling pathways, providing the potential for improved efficacy compared to anti-CD40 receptor approaches.
Quoted from its 10-K, filed 19 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 17 Sept 2014
- Employees
- 33
- Website
- eledon.com ↗
- Head office
- 19800 MACARTHUR BLVD., IRVINE, CA, 92612
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Keith KatkinIndependent Chairman of the Board$191,100
- Dr. Steven PerrinPresident, Chief Scientific Officer, Director, since 2020$4.6m
- Dr. David-Alexandre GrosChief Executive Officer, Director, since 2020$5.6m
- Mr. Paul LittleChief Financial Officer$3.1m
- Mr. Bryan SmithChief Compliance Officer, General Counsel, Corporate Secretary$1.7m
- Dr. Jan HillsonIndependent Director$54,600
- Dr. Allan KirkIndependent Director$61,080
- Dr. June LeeIndependent Director$73,710
- Mr. John McBrideIndependent Director, since 2014$72,345
- Mr. James RobinsonIndependent Director$70,980
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Eledon Pharmaceuticals focuses on the CD40L pathway for organ transplant treatments and autoimmune diseases.
- Tegoprubart, an anti-CD40L antibody, offers improved safety and dosing advantages.
- The company has a clinical stage development with a lead compound targeting ALS and autoimmune conditions.
Weaknesses
- Eledon employs only 17 full-time employees in a clinical stage biotechnology sector.
- The company's IPO in 2014 has not yet resulted in commercialized products.
- Eledon's lead compound is still in development without approved treatments.
Opportunities
- The growing market for autoimmune disease treatments presents a significant opportunity for Eledon.
- The CD40L pathway research could expand into new therapeutic areas beyond current focus.
- Eledon's technology may attract partnerships with larger pharmaceutical companies.
Threats
- Competition from established biotech firms in the CD40L pathway research space is increasing.
- Regulatory hurdles for new biologics could delay product approvals.
- The high costs of clinical trials may strain the company's limited resources.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.